p38α MAPK as a Target for CNS Drug Discovery
Author Information
Author(s): Aaron S Borders, Lucia de Almeida, Linda J Van Eldik, D Martin Watterson
Primary Institution: Northwestern University
Hypothesis
Is p38α MAPK a viable drug discovery target for central nervous system disorders?
Conclusion
p38α MAPK is a promising target for developing treatments for CNS disorders linked to proinflammatory cytokine overproduction.
Supporting Evidence
- p38α MAPK is involved in the regulation of proinflammatory cytokines in the CNS.
- Clinical studies suggest that targeting p38α MAPK may help in treating neurodegenerative diseases.
- Animal models show that p38α MAPK inhibitors can reduce brain injury and inflammation.
Takeaway
Scientists are looking at a protein called p38α MAPK to help create new medicines for brain diseases that involve too many inflammatory signals.
Methodology
The review discusses the role of p38α MAPK in regulating proinflammatory cytokines and its potential as a drug target in CNS disorders.
Limitations
The review primarily focuses on existing literature and does not present new experimental data.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website